Electronic consent represents an exciting area where technology can truly improve the clinical research process.
Seattle, WA (PRWEB) October 03, 2013
Quorum Review IRB, the industry leader in central IRB services, announces it will join with Consent Solutions to discuss eConsenting at the 2013 Forum on Optimizing Clinical Research Performance. The event will be hosted by CenterWatch and iiBIG.
Quorum’s J. Claire Carbary, JD, CIP, will partner with Consent Solutions’ CEO, Susan G. Brink, DrPH to deliver the presentation, “e-Informed Consent Form: Benefits and Challenges” on Thursday, October 17, 2013 from 11:15AM to 12:10PM at The Venetian in Las Vegas.
The presentation will examine implementation lessons learned from the viewpoint of the IRB, the consent provider, and the sponsors and clinical sites. Attendees can expect discussions on IRB review and approval of eConsents, as well as how to use them, special requirements for review, and possible pitfalls.
“Electronic consent represents an exciting area where technology can truly improve the clinical research process,” Ms. Carbary says. "I look forward to sharing the insight that Dr. Brink and I have developed through our own experiences with this technology."
For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.
About Quorum Review IRB
Quorum Review is an independent review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the United States and internationally, a specialized Phase I team, and unique processes for post-approval and registry studies.
Director, Client Relations & Marketing
Quorum Review IRB